Latest research on dexlansoprazole

TAK-390MR is an investigational for the treatment of acid related disorders.. TAK-390MR employs a new modified release (MR) technology on an enantiomer of lansoprazole.

Latest findings

CYP2C19 inhibitors included Omeprazole and esOmeprazole, and CYP2C19 non-inhibitors included dexlansoprazole, lansoprazole, Pantoprazole, and Rabeprazole [18,19]. [source, 2016]
Pantoprazole and dexlansoprazole were the only PPIs with a significant increased use post-safety communication (3.9% vs. 6.1% and 0.0% vs. 0.5%, respectively) ( [source, 2016]
Patients transferring from CYP2C19 inhibitors mainly took the non-inhibitor PPIs Pantoprazole and dexlansoprazole. [source, 2016]
dexlansoprazole also had a significant increase in the frequency of prescription (0.0% vs. 2.5%), the probability of which increased dramatically (OR = 72.55; p < 0.001) ( [source, 2016]
However, it should be noted that dexlansoprazole was initially approved in January 2009, making it difficult to establish a link between the increased use and the FDA Safety Communication. [source, 2016]
In the current study, the main decreases were observed for esomeprazole, followed by lansoprazole; which were partially replaced by Pantoprazole and dexlansoprazole. [source, 2016]
Pantoprazole and dexlansoprazole are the only two PPIs that had an increase in their prescription trends during the post-safety communication period. [source, 2016]
In October 2011 the Pantoprazole and dexlansoprazole drug labels were changed to indicate no important clinical impact on Clopidogrel metabolism [21,22]. [source, 2016]
In addition, studies published in 2010 [23] and 2011 [24] for Pantoprazole and in 2012 for dexlansoprazole [25] showed reduced metabolic drug-drug interaction with Clopidogrel, compared to Omeprazole. [source, 2016]
Finally, dexlansoprazole was launched in 2009, and market share progressively increased. [source, 2016]